This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

This study has been terminated.
(Slow inclusion resulting in premature termination due to logistics)
IMK Fonden
Information provided by:
Hvidovre University Hospital Identifier:
First received: February 3, 2006
Last updated: August 29, 2011
Last verified: September 2006
To examine the influence of regular hypnotic therapy on the incidence of delirium after hip fracture surgery

Condition Intervention Phase
Hip Fracture Delirium Drug: Zolpidem Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • Incidence and severity of postoperative delirium

Secondary Outcome Measures:
  • Sleep quality
  • mobilization
  • loss of functional ability
  • length of stay
  • sedation
  • nocturnal nursing events

Estimated Enrollment: 96
Study Start Date: February 2004
Study Completion Date: January 2007
Detailed Description:
Delirium is prevalent after hip fracture surgery. Delirium has been linked to postoperative sleep disturbances. Zolpidem is a non-benzodiazepine hypnotic that preserves REM sleep. The present study investigates the incidence of delirium in hip fracture patients randomized to Zolpidem treatment 5 mg vs placebo in the perioperative phase.

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary hip fracture, no substance abuse, no regular opioid, corticosteroid or benzodiazepine therapy, hepatic insufficiency, myastenia gravis, allergies to drug components

Exclusion Criteria:

  • Severe respiratory insufficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00286936

Hvidovre University Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
IMK Fonden
Study Director: Nicolai B Foss, MD Hvidovre University Hospital
  More Information Identifier: NCT00286936     History of Changes
Other Study ID Numbers: HHSG-RCT-05
Study First Received: February 3, 2006
Last Updated: August 29, 2011

Keywords provided by Hvidovre University Hospital:
Hip fracture
sleep disturbance

Additional relevant MeSH terms:
Fractures, Bone
Hip Fractures
Wounds and Injuries
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Femoral Fractures
Hip Injuries
Leg Injuries
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017